Complete protection against aflatoxin B1-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold

Cancer Prevention Research

Volumn 7, Issue 7, 2014, Pages 658-665

  Johnson, Natalie M ^a,f   Egner, Patricia A ^a   Baxter, Victoria K ^b   Sporn, Michael B ^c   Wible, Ryan S ^d   Sutter, Thomas R ^d   Groopman, John D ^a   Kensler, Thomas W ^a,e   Roebuck, Bill D ^c  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MEMPHIS   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 CYANO 3,12 DIOXOOLEANA 1,9(11)DIEN 28 OYL]IMIDAZOLE; ACETYLCYSTEINE; AFLATOXIN B1; DNA; GLUTATHIONE; GUANINE 7 OXIDE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNCLASSIFIED DRUG; 1-(2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OYL) IMIDAZOLE; AFLATOXIN B1-DNA ADDUCT; DNA ADDUCT; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, RAT; IMIDAZOLE DERIVATIVE; OLEANOLIC ACID; POISON; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DNA ADDUCT; DRUG DETOXIFICATION; DRUG EFFICACY; FISCHER 344 RAT; GENOTOXICITY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; METABOLITE; MOLECULAR PATHOLOGY; NONHUMAN; PRECANCER; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; URINALYSIS; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; DNA DAMAGE; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; PRECANCEROUS CONDITIONS;

AFLATOXIN B1; ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DNA ADDUCTS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; IMIDAZOLES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; OLEANOLIC ACID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POISONS; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344;

EID: 84904294844     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0430     Document Type: Article

References (47)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J. Cancer 2010;127:2893-917.
2. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: A risk assessment. Environ Health Perspect 2010;118:818-24.
3. Turner PC, Sylla A, Gong YY, Diallo MS, Sutcliffe AE, Hall AJ, et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in West Africa: Acommunity-based intervention study. Lancet 2005;365:1950-6. (Pubitemid 40797504)
4. Chen J, Egner PA, Ng D, Jacobson LP, Muñoz A, Zhu Y, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of china. Cancer Prev Res 2013;6: 1038-45.
5. Roebuck BD, Liu YL, Rogers AE, Groopman JD, Kensler TW. Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): Predictive role for short-term molecular dosimetry. Cancer Res 1991;51: 5501-6.
6. Kensler TW, Gange SJ, Egner PA, Dolan PM, Muñoz A, Groopman JD, et al. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer Epidemiol Biomarkers Prev 1997;6:603-10. (Pubitemid 27342683)
7. Kensler TW, Roebuck BD, Wogan GN, Groopman JD. Aflatoxin: A 50-year odyssey of mechanistic and translational toxicology. Toxicol Sci 2011;120 Suppl 1:S28-S48.
8. 1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999;91:347-54.
9. Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1, 9(11)-dien-28-oyl]imidazole. Cancer Res 2006;66:2488-94.
10. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, et al. Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005;102:4584-9. (Pubitemid 40397155)
11. Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007;6:154-62. (Pubitemid 46206678)
12. Honda T, Honda Y, Favaloro FG Jr., Gribble GW, Suh N, Place AE, et al. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 2002;12: 1027-30. (Pubitemid 34242794)
13. Eustis SL, Boorman GA, Harada T, Popp JA. Liver. In: Boorman GA, Eustis SL, Elwell MR, Montgomery CA, MacKenzie WF, editors. Pathology of the Fischer rat. New York: Academic Press; 1999. p. 71-94.
14. 7-guanine in human urine by high-performance liquid chromatography and isotope dilution tandem mass spectrometry. Chem Res Toxicol 2006;19:1191-5.
15. Kensler TW, Groopman JD, Eaton DL, Curphey TJ, Roebuck BD. Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional enzyme inducer 1,2-dithiole-3-thione. Carcinogenesis 1992;13:95-100.
16. 1-induced hepatic toxicity as short-term screen of cancer chemopreventive dithiolethiones. Fund Appl Toxicol 1996; 32:250-9.
17. 1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis 1985;6: 759-63.
18. Tran QT, Xu L, Phan V, Goodwin SB, Rahman M, Jin VX, et al. Chemical genomics of cancer chemopreventive dithiolethiones. Carcinogenesis 2009;30:480-6.
19. Auerbach SS, Shah RR, Mav D, Smith CS, Walker NJ, Vallant MK, et al. Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. Toxicol Appl Pharmacol 2010;243:300-14.
20. 1 gene signature in rat archival tissues. Chem Res Toxicol 2012;25:1132-44.
21. Merrick BA, Phadke DP, Auerbach SS, Mav D, Stiegelmeyer SM, Shaf RR, et al. RNA-Seq profiling reveals novel hepatic gene expression pattern in aflatoxin B1 treated rats. PLoS ONE 2013;8:e61768.
22. Stefanski SA, Elwell MR. Speen, lymph nodes, and thymus. In:Boorman GA, Eustis SL, Elwell MR, Montgomery CA, MacKenzie WF, editors. Pathology of the Fischer Rat. New York: Academic Press; 1990. p. 369-93.
23. Montgomery CA, Seely JC. Kidney. In:Boorman GA, Eustis SL, Elwell MR, Montgomery CA, MacKenzie WF, editors. Pathology of the Fischer Rat. New York: Academic Press, 1990. p. 127-53.
24. Kensler TW, Davis EF, Bolton MG, Eaton D, Groopman J. Strategies for chemoprotection against aflatoxin-induced liver cancer. In: Eaton DL, Groopman JD, editors. San Diego, CA: Academic Press; 1993. p. 281-306.
25. Kensler TW, Groopman JD, Sutter TR, Curphey TJ, Roebuck BD. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem Res Toxicol 1999;12:113-26. (Pubitemid 29096057)
26. Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oly]imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β. Mol Cancer Ther 2006;5:3232-9. (Pubitemid 46092066)
27. Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, et al. The synthetic triterpenoids CDDO-methylester and CDDO-ethylamide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 2007;67:2414-1419.
28. Laishes BA, Roberts E, Farber E. In vitro measurement of carcinogen-resistant liver cells during hepatocarcinogenesis. Int J Cancer 1978;21:186-193. (Pubitemid 8271911)
29. Neal G, Metcalfe S, Legg R, Judah D, Green J. Mechanism of the resistance to cytotoxicity which precedes aflatoxin B1 hepatocarcinogenesis. Carcinogenesis 1981;2:457-61. (Pubitemid 11082672)
30. 1 in the rat. Toxicol Appl Pharmacol 1988;93:442-51.
31. 1: patterns of DNA adduct formation, removal, and excretion in relation to carcinogenesis. Drug Metab Rev 1982;13:581-602.
32. Bailey EA, Iyra RS, Stone MP, Harris TM, Essigmann JM. Mutational properties of the primary aflatoxin B1-DNA adduct. Proc Natl Acad Sci USA 1996;93:1535-9. (Pubitemid 26075159)
33. 1 formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci USA 2002;99:6655-60.
34. Leadon SA, Snowden MM. Differential repair of DNA damage in the human metallothionein gene family. Mol Cell Biol 1988;8:5331-8.
35. Dobo KL, Fiedler RD, Gunther WC, Thiffeault CJ, Cammerer Z, Coffing SL, et al. Defining EMS and ENU dose-response relationships using the Pig-a mutation assay in rats. Mutat Res 2011;725:13-21.
36. Jenkins GJ, Zaïr Z, Johnson GE, Doak SH. Genotoxic thresholds, DNA repair, and susceptibility in human populations. Toxicology 2010;278:305-10.
37. Thomas AD, Jenkins GJ, Kaina B, Bodger OG, Tomaszowski K, Lewis PD, et al. Influence of DNA repair on nonlinear dose-responses for mutation. Toxicol Sci 2013;132:87-95.
38. 1-DNA adduct formed in vivo in rat liver. Proc Natl Acad Sci USA 1978;75:1745-9.
39. 1 in rats at very low exposures. Cancer Res 1982;42:3659-62.
40. 1. Carcinogenesis 1990;11:2133-5.
41. Lutz WK. Quantitative evaluation of DNA binding data for risk estimation and for classi fication of direct and indirect carcinogens. J Cancer Res Clin Oncol 1986;112:85-91. (Pubitemid 16001177)
42. 1-DNA adduct formation in the rat in vivo and in vitro: The use of immunoslot blotting for adduct quantitation. Teratog Carcinog Mutagen 1999;19:157-70.
43. 1 binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis 1986;7:853-8.
44. 1-macromolecular adducts in rats and humans at dietary levels of exposure. Food Chem Toxicol 2004;42: 559-69.
45. 1-DNA adducts: Linear correlation with hepatic cancer risk. Regul Toxicol Pharmacol 1989;10:74-81.
46. 1: evidence for an inducible repair response. Cancer Res 1987;47:1993-2001.
47. Waters MD, Jackson M, Lea I. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. Mutat Res 2010;705:184-200.